Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasmine Zain

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
Blood Advances|April 10, 2019
Targeting CD47 in Sézary syndrome with SIRPαFcLisa D S Johnson, Swati Banerjee, Oleg Kruglov, et al.
Blood Advances|June 22, 2021
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplantMonzr M Al Malki, Ni-Chun Tsai, Joycelynne Palmer, et al.
The Lancet. Haematology|July 27, 2024
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 studyAlex F Herrera, Jasmine Zain, Kerry J Savage, et al.
Blood|June 14, 2022
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Blood|August 1, 2022
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
British Journal of Haematology|February 2, 2022
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplantMalvi Savani, Kwang W Ahn, Yue Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 29, 2019
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell LymphomaStefan K Barta, Jasmine Zain, Alexander W MacFarlane, et al.
Transplantation and Cellular Therapy|March 2, 2024
A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell LymphomaMuhamad Alhaj Moustafa, Jeremy L Ramdial, Athanasios Tsalatsanis, et al.
British Journal of Haematology|September 19, 2022
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphomaFateeha Furqan, Kwang W Ahn, Yue Chen, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
Blood Advances|April 10, 2019
Targeting CD47 in Sézary syndrome with SIRPαFcLisa D S Johnson, Swati Banerjee, Oleg Kruglov, et al.
Blood Advances|June 22, 2021
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplantMonzr M Al Malki, Ni-Chun Tsai, Joycelynne Palmer, et al.
The Lancet. Haematology|July 27, 2024
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 studyAlex F Herrera, Jasmine Zain, Kerry J Savage, et al.
Blood|June 14, 2022
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Blood|August 1, 2022
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
British Journal of Haematology|February 2, 2022
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplantMalvi Savani, Kwang W Ahn, Yue Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 29, 2019
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell LymphomaStefan K Barta, Jasmine Zain, Alexander W MacFarlane, et al.
Transplantation and Cellular Therapy|March 2, 2024
A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell LymphomaMuhamad Alhaj Moustafa, Jeremy L Ramdial, Athanasios Tsalatsanis, et al.
British Journal of Haematology|September 19, 2022
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphomaFateeha Furqan, Kwang W Ahn, Yue Chen, et al.
Pageof 10